The pharmaceutical excipients industry is undergoing significant changes, which are the result of technological advancements, regulatory policy adjustments, and changes in consumer demand. The Chinese biopharmaceutical industry is expected to drive strong demand for high-performance excipients, with its value projected to exceed 700 billion yuan by 2025. At the same time, the National Medical Products Administration (NMPA) has established new good manufacturing practice (GMP) requirements for excipients. These regulations will come into effect on January 1, 2026, prioritizing quality control and traceability. These policies aim to promote the development of large enterprises and accelerate industry consolidation by aligning domestic laws with international standards.
